Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

被引：102

作者：

Hodi, F. Stephen

Sznol, Mario

Kluger, Harriet M.

McDermott, David F.

Carvajal, Richard D.

Lawrence, Donald P.

Topalian, Suzanne Louise

Atkins, Michael B.

Powderly, John D.

Sharfman, William Howard

Puzanov, Igor

Smith, David C.

Leming, Philip D.

Lipson, Evan J.

Taube, Janis M.

Anders, Robert

Horak, Christine E.

Kollia, Georgia

Gupta, Ashok Kumar

Sosman, Jeffrey Alan

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[6] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[7] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[8] Carolina BioOncol Inst, Huntersville, NC USA

[9] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Christ Hosp, Ctr Canc, Cincinnati, OH 45219 USA

[12] Bristol Myers Squibb Co, Princeton, NJ USA

[13] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.9002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9002

引用

页数：1